ECM
CYTK icon

ExodusPoint Capital Management’s Cytokinetics CYTK Stock Holding History

ExodusPoint Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$804K – 1559
2025
Q1 		$804K Buy
+20,000
New +$919K 0.01% 976
2024
Q2 		– Sell
-7,400
Closed -$520K – 1612
2024
Q1 		$520K Buy
+7,400
New +$572K ﹤0.01% 1128

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ExodusPoint Capital Management's CYTK Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Cytokinetics (CYTK) stake by 85% in Q1 2026, selling an estimated $18.5M and leaving 52,227 shares worth $3.44M. The position accounts for 0.03% of the portfolio, ranked #565.

ExodusPoint Capital Management first reported a position in CYTK in Q4 2019 and has held it in 18 quarters since. The position peaked at $21.8M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • ExodusPoint Capital Management held 52,227 shares of Cytokinetics worth $3.44M as of Q1 2026.
  • ExodusPoint Capital Management sold 290,917 Cytokinetics shares in Q1 2026, an estimated $18.5M.
  • Cytokinetics made up 0.03% of ExodusPoint Capital Management's portfolio in Q1 2026, its #565 holding.
  • ExodusPoint Capital Management first reported a position in Cytokinetics in Q4 2019 and has held it in 18 quarters since.
  • ExodusPoint Capital Management's Cytokinetics position peaked at $21.8M in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.